Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.

Atherosclerosis - 1 Nov 2016

Roth Eli M, Moriarty Patrick M, Bergeron Jean, Langslet Gisle, Manvelian Garen, Zhao Jian, Baccara-Dinet Marie T, Rader Daniel J

Abstract excerpt

BACKGROUND AND AIMS: In previous phase III studies, the PCSK9 monoclonal antibody alirocumab was administered at doses of 75 or 150 mg every 2 weeks (Q2W). CHOICE I (NCT01926782) evaluated 300 mg every 4 weeks (Q4W) in patients on either maximally tolerated statin or no statin, both ± other lipid-lowering therapies. METHODS: CHOICE I included patients with hypercholesterolemia at moderate-to-very-high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Atorvastatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypercholesterolemia

Share to Proprotein Convertase 9

Share to Simvastatin

Source

Identifiers

PMID: 27639753
DOI: 10.1016/j.atherosclerosis.2016.08.043

Genes

PCSK9

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.PMID 27639753Read ↗

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.Semantic proximity Read ↗

Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.Semantic proximity Read ↗

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.Semantic proximity Read ↗

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.Semantic proximity Read ↗

Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL CholesterolSemantic proximity Read ↗

Long-term Effectiveness of PCSK9 Inhibitors versus Ezetimibe as Adjunctive Therapy to Statins in Patients with Atherosclerotic Cardiovascular Disease: A TriNetX Database AnalysisSemantic proximity Read ↗

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.Semantic proximity Read ↗

Evolocumab in patients with homozygous familial hypercholesterolemia in India.Semantic proximity Read ↗

PCSK9: From discovery to therapeutic applications.Semantic proximity Read ↗

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.Semantic proximity Read ↗

Inclisiran—Silencing the Cholesterol, Speaking up the PrognosisSemantic proximity Read ↗

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.